



## **Neovacs TNF-Kinoid selected by Windhover and Healogix as one of the Top 10 Inflammatory/Autoimmune Projects to Watch**

**Paris, October 11, 2010 - Neovacs (Alternext Paris: ALNEV), a biotech company focused on an active immunotherapy technology platform (Kinoids™) with applications in the treatment of autoimmune diseases, inflammatory diseases and cancer, announced today that its TNF-Kinoid product candidate has been selected by Windhover Information, the international pharmaceutical and healthcare information company, as one of the Top Ten Projects to Watch in the inflammatory/autoimmune area. In addition, Neovacs has been invited to present its TNF-Kinoid programs at the Therapeutic Area Partnerships meeting, which will take place at the Westin Copley Place in Boston, MA. from 2 to 4 November 2010.**

The selection committee was made up of pharmaceutical industry experts, including members of the editorial team of Windhover's publications, IN VIVO and START-UP. Selected companies had to meet rigorous criteria, including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.

*"We are delighted to have been recognized in this way by such a group of international pharmaceutical industry experts," commented Guy-Charles de la Horie, Neovacs' CEO. "This distinction is a great opportunity for us to raise the profile of our TNF-Kinoid treatment, a novel approach for inflammatory and autoimmune diseases. The product candidate awarded by Windhover is currently in clinical development for both Crohn's disease and rheumatoid arthritis, with encouraging preliminary results available in the first of these indications."*

*"The projects selected as one of the Top Ten to Watch and which will therefore be presented at our conference in Boston had to pass a stringent selection process managed by our expert panel" said David Cassak, Vice President, Content, Windhover Conferences, a Division of Elsevier Business Intelligence. He added: "the projects needed both to represent a genuine innovation in the treatment of inflammatory and autoimmune diseases and meet rigorous criteria."*

Neovacs plans to present the clinical progress achieved to date with its TNF-Kinoid. Final results of a Phase 1/2 study in 21 patients with Crohn's Disease are expected to be available by the end of 2010. The TNF-Kinoid is in phase 2 testing in rheumatoid arthritis, and passed an important milestone this last July with the consent of the independent Data and Safety Monitoring Board to initiate administration of a higher dose, attesting to the good tolerance of the therapy to date. Preliminary results from this study, which is planned to recruit 48 patients, are expected in the first half of 2011.

Windhover's annual Therapeutic Area Partnerships meeting is amongst the industry's most targeted and

efficient partnering meetings for life science companies seeking partnerships in the top therapeutic areas, Oncology, Cardiovascular/Metabolic, Neuroscience, Infectious, Inflammatory Diseases and other therapeutic areas. Decision-makers (business development and R & D) focusing on these therapeutic categories can meet to develop strategic alliances between their companies. *"It is interesting to look at the roster of Companies selected as Top 10 and presenting in previous years"* said Piers Whitehead, VP of Corporate Development at Neovacs. *"The list includes companies such as Myogen, Trophos, BiPar, Sirtris and Kosan Bioscience, which all went on to do interesting deals with other biopharma companies"*

For more information on the meeting: [www.tapartnerships.com](http://www.tapartnerships.com).

### **About Neovacs**

Neovacs is a biotechnology company focused on an active immunotherapy technology platform (Kinoids™) with applications in autoimmune diseases and other chronic conditions. Neovacs' current portfolio consists of 3 drug candidates: TNF-Kinoid, IFN $\alpha$ -Kinoid and VEGF-Kinoid. The company's lead immunotherapy program (TNF-Kinoid) targets TNF-mediated chronic inflammatory diseases. For TNF-Kinoid, a Phase I/II clinical trial in Crohn's disease and a Phase II trial in rheumatoid arthritis (RA) are ongoing. The latter clinical study is also the focus of collaboration with the French diagnostics company BMD, with the goal of developing theranostic tools for personalized care in RA. Patient recruitment is ongoing in a Phase I/II trial of Neovacs' second product candidate (IFN $\alpha$  -Kinoid, an immunotherapy targeting interferon alpha) in the treatment of lupus. Neovacs' R&D has generated a broad patent estate. Neovacs' key historical investors are Truffle, Novartis Venture Fund and OTC asset management.

**For more information, visit the Neovacs web site at [www.neovacs.com](http://www.neovacs.com)**

### **About Windhover**

Windhover Information Inc., an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, *IN VIVO: The Business & Medicine Report*, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see [www.windhover.com](http://www.windhover.com).

### **Contacts**

#### **Presse - Alize RP**

Caroline Carmagnol  
+33 (0) 6 64 18 99 59  
[caroline@alizerp.com](mailto:caroline@alizerp.com)

#### **Neovacs**

Florence Hocdée - Leroy  
+33 (0) 1 53 10 93 14  
[fhocdeeleroy@neovacs.com](mailto:fhocdeeleroy@neovacs.com)

#### **Investisseurs – Actifin**

Nicolas Meunier  
+ 33 (0) 1 56 88 11 11  
[nmeunier@actifin.fr](mailto:nmeunier@actifin.fr)